A dual-hit animal model for age-related parkinsonism

[1]  A. Eggers.  Why do Alzheimer's disease and Parkinson's disease target the same neurons? , 2009, Medical hypotheses.

[2]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[3]  A. Granholm,et al.  Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice , 2009, Neurobiology of Disease.

[4]  J. Kordower,et al.  Future of cell and gene therapies for Parkinson's disease , 2008, Annals of neurology.

[5]  A. Granholm,et al.  Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFRα1, gene , 2008, Brain Research.

[6]  A. Granholm,et al.  The nigrostriatal dopamine system of aging GFRα‐1 heterozygous mice: neurochemistry, morphology and behavior , 2008, The European journal of neuroscience.

[7]  T. Vanitallie.  Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. , 2008, Metabolism: clinical and experimental.

[8]  M. Tuszynski,et al.  Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Singleton,et al.  Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007 , 2008, Environmental health perspectives.

[10]  J. Kordower,et al.  Age and region‐specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure in monkeys , 2008, Glia.

[11]  A. Toulouse,et al.  Progress in Parkinson's disease—Where do we stand? , 2008, Progress in Neurobiology.

[12]  D. Gao,et al.  Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons , 2008, Neuroscience Research.

[13]  O. Isacson,et al.  Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. , 2008, Brain : a journal of neurology.

[14]  Alberto Albertini,et al.  Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.

[15]  D. Surmeier,et al.  Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. , 2008, Parkinsonism & related disorders.

[16]  H. Braak,et al.  Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered , 2008, Experimental Neurology.

[17]  S. Heermann,et al.  Transforming Growth Factor β Cooperates with Persephin for Dopaminergic Phenotype Induction , 2008, Stem cells.

[18]  A. Granholm,et al.  Mood, memory and movement: an age-related neurodegenerative complex? , 2008, Current aging science.

[19]  R. Pasterkamp,et al.  Getting connected in the dopamine system , 2008, Progress in Neurobiology.

[20]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[21]  D. Galter,et al.  Parkinson’s disease: genetic versus toxin‐induced rodent models , 2008, The FEBS journal.

[22]  P. Carvey,et al.  Neuroinflammation and Peripheral Immune Infiltration in Parkinson's Disease: An Autoimmune Hypothesis , 2008, Cell transplantation.

[23]  J. Chuang,et al.  Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats , 2008, Journal of pineal research.

[24]  M. Sawada,et al.  Effects of Aging on Neuroprotective and Neurotoxic Properties of Microglia in Neurodegenerative Diseases , 2008, Neurodegenerative Diseases.

[25]  J. Salamone,et al.  In vitro generation of dopaminergic neurons from adult subventricular zone neural progenitor cells. , 2008, Stem cells and development.

[26]  D. Berg,et al.  Nutrition and the risk for Parkinson’s disease: review of the literature , 2008, Journal of Neural Transmission.

[27]  Dennis C Harvey,et al.  Methamphetamine increases basal ganglia iron to levels observed in aging , 2007, Neuroreport.

[28]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[29]  A. Granholm,et al.  Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice , 2007, The Journal of Neuroscience.

[30]  J. Langston,et al.  Model fusion: The next phase in developing animal models for parkinson’s disease , 2007, Neurotoxicity Research.

[31]  G. Gerhardt,et al.  Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. , 2007, Journal of neurosurgery.

[32]  P. Carvey,et al.  Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide , 2007, Neurochemistry International.

[33]  H. Braak,et al.  Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons , 2007, Acta Neuropathologica.

[34]  A. Tomac,et al.  A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra , 2006, Experimental Neurology.

[35]  R. McKay,et al.  A Specific Survival Response in Dopamine Neurons at Most Risk in Parkinson's Disease , 2006, The Journal of Neuroscience.

[36]  G. Miller,et al.  Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  A. Granholm,et al.  Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease , 2006, Brain Research.

[38]  F. Fumagalli,et al.  Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease , 2006, The Pharmacogenomics Journal.

[39]  J. O'Callaghan,et al.  Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α , 2006, Journal of neurochemistry.

[40]  M. Smidt,et al.  Developmental origin and fate of meso-diencephalic dopamine neurons , 2006, Progress in Neurobiology.

[41]  A. Granholm,et al.  Partial deletion of glial cell line-derived neurotrophic factor (GDNF) in mice: Effects on sucrose reward and striatal GDNF concentrations , 2006, Brain Research.

[42]  M. Baron.  Movement disorders in the older patient: differential diagnosis and general management. , 2005, Cleveland Clinic journal of medicine.

[43]  D. Brooks,et al.  Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain , 2005, Nature Medicine.

[44]  L. Silvian,et al.  New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors. , 2005, Current topics in medicinal chemistry.

[45]  G. Logroscino,et al.  The Role of Early Life Environmental Risk Factors in Parkinson Disease: What Is the Evidence? , 2005, Environmental health perspectives.

[46]  M. Bannon.  The dopamine transporter: role in neurotoxicity and human disease. , 2005, Toxicology and applied pharmacology.

[47]  J. Kordower,et al.  Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism , 2005, Experimental Neurology.

[48]  B. Yamamoto,et al.  High-Dose Methamphetamine Acutely Activates the Striatonigral Pathway to Increase Striatal Glutamate and Mediate Long-Term Dopamine Toxicity , 2004, The Journal of Neuroscience.

[49]  M. Saarma,et al.  Increased extracellular dopamine concentrations and FosB/ΔFosB expression in striatal brain areas of heterozygous GDNF knockout mice , 2004, The European journal of neuroscience.

[50]  R. Burke.  Ontogenic cell death in the nigrostriatal system , 2004, Cell and Tissue Research.

[51]  D. Hess,et al.  Minocycline Up-regulates Bcl-2 and Protects against Cell Death in Mitochondria* , 2004, Journal of Biological Chemistry.

[52]  J. P. Card,et al.  Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity , 2004, Experimental Neurology.

[53]  G. C. Wagner,et al.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. , 2003, Journal of pharmacological sciences.

[54]  M. Morales,et al.  Differential expression of the cell line-derived neurotrophic factor (GDNF) receptor GFRα1 in heterozygous Gfrα1 null-mutant mice after stroke , 2003, Neuroscience Letters.

[55]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[56]  B. Hoffer,et al.  The Noradrenergic System of Aged GDNF Heterozygous Mice , 2003, Cell transplantation.

[57]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[58]  R. Levi‐montalcini.  The nerve growth factor and the neuroscience chess board. , 2003, Progress in brain research.

[59]  M. Malcangio.  GDNF and somatostatin in sensory neurones. , 2003, Current opinion in pharmacology.

[60]  J. Bertram,et al.  Nephron Number, Renal Function, and Arterial Pressure in Aged GDNF Heterozygous Mice , 2003, Hypertension.

[61]  J. Rinne,et al.  Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease , 2002, Neuroscience & Biobehavioral Reviews.

[62]  W. Cass,et al.  Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats , 2002, Brain Research.

[63]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[64]  Gene-Jack Wang,et al.  Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence , 2001, Journal of Neuroscience.

[65]  H. Phillips,et al.  Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation , 2001, The European journal of neuroscience.

[66]  A. Gow,et al.  Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment , 2001, Brain Research Reviews.

[67]  J. Drago,et al.  Nephron endowment in glial cell line-derived neurotrophic factor (GDNF) heterozygous mice. , 2001, Kidney international.

[68]  J. Koistinaho,et al.  Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.

[69]  B. Fiebich,et al.  Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia , 2001, The Journal of Neuroscience.

[70]  J S Fowler,et al.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. , 2001, The American journal of psychiatry.

[71]  D. Yurek,et al.  Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion , 2001, Brain Research.

[72]  B. V. Houten,et al.  DNA damage in brain mitochondria caused by aging and MPTP treatment , 2000, Brain Research.

[73]  M. Saarma.  GDNF – a stranger in the TGF-β superfamily? , 2000 .

[74]  C. Bates.  Kidney development: regulatory molecules crucial to both mice and men. , 2000, Molecular genetics and metabolism.

[75]  D. Ingram.  Age-related decline in physical activity: generalization to nonhumans. , 2000, Medicine and science in sports and exercise.

[76]  A. Granholm,et al.  Glial Cell Line-Derived Neurotrophic Factor Is Essential for Postnatal Survival of Midbrain Dopamine Neurons , 2000, The Journal of Neuroscience.

[77]  D. Yurek,et al.  Lesion-Induced Increase of BDNF Is Greater in the Striatum of Young versus Old Rat Brain , 2000, Experimental Neurology.

[78]  M. Naoi,et al.  Cell death of dopamine neurons in aging and Parkinson’s disease , 1999, Mechanisms of Ageing and Development.

[79]  D. Mash,et al.  Dopamine transporter‐immunoreactive neurons decrease with age in the human substantia nigra , 1999, The Journal of comparative neurology.

[80]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[81]  B. Yamamoto,et al.  The effects of methamphetamine on the production of free radicals and oxidative stress. , 1998, The Journal of pharmacology and experimental therapeutics.

[82]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[83]  G. Gerhardt,et al.  Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats , 1998, Brain Research.

[84]  N. Volkow,et al.  Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. , 1998, The American journal of psychiatry.

[85]  S. Leff,et al.  Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[86]  S H Ferris,et al.  Motor/Psychomotor Dysfunction in Normal Aging, Mild Cognitive Decline, and Early Alzheimer's Disease: Diagnostic and Differential Diagnostic Features , 1997, International Psychogeriatrics.

[87]  G. Gerhardt,et al.  Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[88]  N. Belluardo,et al.  Complementary and Overlapping Expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF), c-ret Proto-Oncogene, and GDNF Receptor-α Indicates Multiple Mechanisms of Trophic Actions in the Adult Rat CNS , 1997, The Journal of Neuroscience.

[89]  A. Granholm,et al.  Morphological Alterations in the Peripheral and Central Nervous Systems of Mice Lacking Glial Cell Line-Derived Neurotrophic Factor (GDNF): Immunohistochemical Studies , 1997, The Journal of Neuroscience.

[90]  Jonas Frisén,et al.  Renal agenesis and the absence of enteric neurons in mice lacking GDNF , 1996, Nature.

[91]  I. Fariñas,et al.  Renal and neuronal abnormalities in mice lacking GDNF , 1996, Nature.

[92]  Mart Saarma,et al.  Defects in enteric innervation and kidney development in mice lacking GDNF , 1996, Nature.

[93]  J S Fowler,et al.  PET evaluation of the dopamine system of the human brain. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[94]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[95]  L A Beckett,et al.  Prevalence of parkinsonian signs and associated mortality in a community population of older people. , 1996, The New England journal of medicine.

[96]  S. Shimohama,et al.  Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. , 1995, Neurosurgery.

[97]  A. Granholm,et al.  Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons , 1995, The Journal of comparative neurology.

[98]  Shelley R. Winn,et al.  Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.

[99]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[100]  J. O'Callaghan,et al.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.

[101]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[102]  P. Bickford,et al.  Impaired acquisition of novel locomotor tasks in aged and norepinephrine-depleted F344 rats , 1992, Neurobiology of Aging.

[103]  P. Sonsalla,et al.  Characteristics of Dopaminergic Neurotoxicity Produced by MPTP and Methamphetamine a , 1992, Annals of the New York Academy of Sciences.

[104]  W. Slikker,et al.  The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. , 1992, The Journal of pharmacology and experimental therapeutics.

[105]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[106]  S. O'dell,et al.  Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity , 1991, Brain Research.

[107]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[108]  M. Verrier,et al.  Different rates of age-related loss for four murine monoaminergic neuronal populations , 1991, Neurobiology of Aging.

[109]  W. Gibb,et al.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[110]  T. McNeill,et al.  Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice , 1990, Brain Research.

[111]  W. Nicklas,et al.  Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. , 1989, Science.

[112]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[113]  R. Mair,et al.  Neurochemical specificity of learning: dopamine and motor learning. , 1987, The Yale journal of biology and medicine.

[114]  R. Guillery,et al.  Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain , 1982, Brain Research.

[115]  J. Gibb,et al.  Long-term effects of methamphetamine on the synthesis and metabolism of 5-hydroxytryptamine in various regions of the rat brain , 1981, Neuropharmacology.

[116]  J. Gibb,et al.  Blockade of methamphetamine-induced depression of tyrosine hydroxylase by GABA transaminase inhibitors. , 1980, European journal of pharmacology.

[117]  L. Seiden,et al.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.

[118]  S. T. Mason,et al.  An investigation of the role of cortical and cerebellar noradrenaline in associative motor learning in the rat , 1977, Brain Research.

[119]  C J CLEMEDSON,et al.  DYNAMIC RESPONSE OF CHEST WALL AND LUNG INJURIES IN RABBITS EXPOSED TO AIR SHOCK WAVES OF SHORT DURATION. , 1964, Acta physiologica Scandinavica. Supplementum.

[120]  B. Falck,et al.  SOME OBSERVATIONS ON THE HISTOLOGY AND HISTOCHEMISTRY OF THE CHROMAFFIN CELLS PROBABLY STORING DOPAMINE , 1959, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[121]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[122]  A. Surguchov.  Molecular and cellular biology of synucleins. , 2008, International review of cell and molecular biology.

[123]  R. Burke.  GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. , 2006, Journal of neural transmission. Supplementum.

[124]  A. Kakita,et al.  Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. , 2006, Journal of Neuropathology and Experimental Neurology.

[125]  S. DeKosky,et al.  Monoamine neurons in aging and Alzheimer's disease , 2005, Journal of Neural Transmission / General Section JNT.

[126]  K. Suzuki,et al.  Age-related changes in human D1 dopamine receptors measured by positron emission tomography , 2005, Psychopharmacology.

[127]  P. Janak,et al.  GDNF and Addiction , 2005, Reviews in the neurosciences.

[128]  Moussa B. H. Youdim,et al.  Neuroprotective Strategies in Parkinson’s Disease , 2003, CNS drugs.

[129]  S. Shelton,et al.  Noninvasive assessment of aromatic L‐amino acid decarboxylase activity in aging rhesus monkey brain in vivo , 2001, Synapse.

[130]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[131]  P. Bickford.  Aging and Motor Learning: A Possible Role for Norepinephrine in Cerebellar Plasticity , 1995, Reviews in the neurosciences.

[132]  K. Unsicker,et al.  Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. , 1995, Journal of neural transmission. Supplementum.

[133]  A. Carlsson.  Development of new pharmacological approaches in Parkinson's disease. , 1987, Advances in neurology.

[134]  R. Bartus,et al.  Age-related differences in behavior across the life span of the C57BL/6J mouse. , 1981, Experimental aging research.

[135]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.